Natalizumab (Solution)

• Description:

  Natalizumab (Solution) (AN100226; BG00002) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1) . Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses[1].

• Product Name Alternative:

  AN100226; BG00002

• UNSPSC:

  12352203

• Target:

  Integrin

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Cytoskeleton

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/natalizumab-solution.html

• Purity:

  99.0

• Solubility:

  10 mM in DMSO

• Smiles:

  [Natalizumab (Solution) ]

• Molecular Weight:

  (146.22 kDa)

• References & Citations:

  [1]Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3 (2) :259-68.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 4

• CAS Number:

  189261-10-7